» Articles » PMID: 38436764

Dynamic YAP Expression in the Non-parenchymal Liver Cell Compartment Controls Heterologous Cell Communication

Abstract

Introduction: The Hippo pathway and its transcriptional effectors yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are targets for cancer therapy. It is important to determine if the activation of one factor compensates for the inhibition of the other. Moreover, it is unknown if YAP/TAZ-directed perturbation affects cell-cell communication of non-malignant liver cells.

Materials And Methods: To investigate liver-specific phenotypes caused by YAP and TAZ inactivation, we generated mice with hepatocyte (HC) and biliary epithelial cell (BEC)-specific deletions for both factors (YAPKO, TAZKO and double knock-out (DKO)). Immunohistochemistry, single-cell sequencing, and proteomics were used to analyze liver tissues and serum.

Results: The loss of BECs, liver fibrosis, and necrosis characterized livers from YAPKO and DKO mice. This phenotype was weakened in DKO tissues compared to specimens from YAPKO animals. After depletion of YAP in HCs and BECs, YAP expression was induced in non-parenchymal cells (NPCs) in a cholestasis-independent manner. YAP positivity was detected in subgroups of Kupffer cells (KCs) and endothelial cells (ECs). The secretion of pro-inflammatory chemokines and cytokines such as C-X-C motif chemokine ligand 11 (CXCL11), fms-related receptor tyrosine kinase 3 ligand (FLT3L), and soluble intercellular adhesion molecule-1 (ICAM1) was increased in the serum of YAPKO animals. YAP activation in NPCs could contribute to inflammation via TEA domain transcription factor (TEAD)-dependent transcriptional regulation of secreted factors.

Conclusion: YAP inactivation in HCs and BECs causes liver damage, and concomitant TAZ deletion does not enhance but reduces this phenotype. Additionally, we present a new mechanism by which YAP contributes to cell-cell communication originating from NPCs.

Citing Articles

The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.

Zhong B, Du J, Liu F, Sun S MedComm (2020). 2025; 6(3):e70128.

PMID: 40066231 PMC: 11892025. DOI: 10.1002/mco2.70128.


Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies.

Wang W, Lian H, Liang Y, Ye Y, Tam P, Chen Y Cells. 2024; 13(23).

PMID: 39682745 PMC: 11640075. DOI: 10.3390/cells13231997.


CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer.

Wesener M, Weiler S, Bissinger M, Klessinger T, Rose F, Merker S Int J Mol Sci. 2024; 25(15).

PMID: 39126118 PMC: 11312940. DOI: 10.3390/ijms25158549.


Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review).

Li S, Hao L, Li N, Hu X, Yan H, Dai E Int J Oncol. 2024; 65(3).

PMID: 39092548 PMC: 11302957. DOI: 10.3892/ijo.2024.5676.


Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression.

Lee N, Choi M, Lee E, Koo J Arch Pharm Res. 2024; 47(6):558-570.

PMID: 38874747 PMC: 11217110. DOI: 10.1007/s12272-024-01501-5.

References
1.
Weiler S, Pinna F, Wolf T, Lutz T, Geldiyev A, Sticht C . Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer. Gastroenterology. 2017; 152(8):2037-2051.e22. DOI: 10.1053/j.gastro.2017.02.018. View

2.
Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L . Animal models of cholestasis: An update on inflammatory cholangiopathies. Biochim Biophys Acta Mol Basis Dis. 2018; 1865(5):954-964. DOI: 10.1016/j.bbadis.2018.07.025. View

3.
Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C . The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147(4):759-72. DOI: 10.1016/j.cell.2011.09.048. View

4.
Weiler S, Lutz T, Bissinger M, Sticht C, Knaub M, Gretz N . TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Cancer Lett. 2020; 473:164-175. DOI: 10.1016/j.canlet.2019.12.044. View

5.
Galli G, Carrara M, Yuan W, Valdes-Quezada C, Gurung B, Pepe-Mooney B . YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. Mol Cell. 2015; 60(2):328-37. PMC: 4624327. DOI: 10.1016/j.molcel.2015.09.001. View